Cannabis Europa Paris 2026 brings together policymakers, clinicians, industry leaders and international experts for a full-day agenda exploring France’s transition from pilot to national medical cannabis access. Across keynotes, policy deep-dives, clinical pathway sessions, market development panels and comparative insights from Canada, Luxembourg and Switzerland, the programme examines the decisions shaping patient access, pharmaceutical standards, reimbursement models and domestic production. Delegates will gain a clear understanding of France’s 2026 framework, practical operational implications for healthcare and industry, and the broader European signals emerging from this historic moment in cannabis policy reform.
